Accelerated Discovery and Development of New Medicines: Prosperity Partnership for a Healthier Nation

GSK是一家全球性医疗保健公司，发现，开发和制造药物，以治疗一系列疾病，包括：呼吸系统疾病，癌症，心脏病，癫痫，细菌和病毒感染（如艾滋病毒和狼疮），以及牛皮癣等皮肤病。GSK每年生产超过40亿包药品，致力于应对社会最大的医疗挑战。除了为患者提供变革性药品的使命，GSK还不断寻求提高我们供应链中发现、生产和交付环节的流程效率和可持续性。事实上，葛兰素史克致力于实现到2050年的宏伟可持续发展目标，而这一目标只有通过更好的路线来制造现有和未来的药物，从分子的首次设计到临床患者的整个过程中推动创新才能实现。这一繁荣合作伙伴关系旨在巩固葛兰素史克与诺丁汉大学和斯特拉斯克莱德大学之间现有的充满活力的合作关系。每个合作伙伴的优势将被利用，以提供一套新的方法和途径，以应对药物发现，开发和制造中的一些重大挑战。我们的愿景是提高原子、能量和时间的效率;以更低的成本生产变革性药物，减少废物产生，缩短生产路线。我们的伙伴关系所涵盖的关键挑战领域或主题包括：1.人工智能（AI）和机器学习的开发和应用，以有效识别下一代药物：在药物发现中，设计、制备和测试数百种候选结构，以找到具有正确特征的分子，以纳入临床。人工智能知情决策的发展有可能通过最大限度地减少这一阶段需要制造的化合物数量来节省大量资金。开发的软件将结合绿色化学原理，目标是所采用的化学方法尽可能有效和可持续。下一代催化和合成：寻求发现新药物的化学家需要新的反应，使他们能够制造和研究目前难以甚至不可能制造的结构。该提案的一个关键目标是开发新的试剂，催化剂和反应，以促进更有效地制备药物样分子，加速药物发现。同样，我们将开发新的方法来执行一些最常见的化学转化在合成药物，同时避免使用致癌试剂。可持续的流程，提供效率和从克到公斤的规模扩大过渡。目前未充分利用的方法，如电化学，将被探索其催化与更便宜和对环境影响较小的金属反应的能力，如用镍取代钯。新的设备数字化设计工具集将实现新型制药加工设备的数字化制造。目前的开发依赖于现有的传统容器和流动反应器，这损害了我们提供以最佳性能运行的工艺的能力。该研究将结合先进的工艺模型、最先进的实验和3D打印/增材制造技术，彻底改变我们开发、扩大和操作化学工艺以提供新药的方式。整合三家合作机构的项目和专业知识，以及成功实现我们的研究目标，将为更广泛的制药行业做出重大贡献，事实上，GSK的使命是更快地发现和开发变革性药物，以帮助人们做得更多，感觉更好，寿命更长。

GSK is a global healthcare company that discovers, develops and manufactures medicines to treat a range of conditions including: respiratory diseases, cancer, heart disease, epilepsy, bacterial and viral infections (such as HIV and lupus), and skin conditions like psoriasis. GSK makes over 4 billion packs of medicines each year, with the goal of playing its part in meeting some of society's biggest healthcare challenges.Alongside a mission to provide transformative medicines to patients, GSK continually seeks to improve the efficiency and sustainability of our processes across the discovery, manufacturing, and delivery components of our supply chain. Indeed, GSK are committed to ambitious sustainability goals by 2050 that can only be achieved by making existing and future medicines via better routes, driving innovation all the way from the first design of the molecule through to patients in the clinic.This Prosperity Partnership aims to build on existing vibrant collaborations between GSK and the Universities of Nottingham and Strathclyde. The strengths of each partner will be leveraged to deliver a new suite of methods and approaches to tackle some of the major challenges in the discovery, development, and manufacture of medicines. Our vision is to increase efficiency in terms of atoms, energy, and time; resulting in transformative medicines at lower costs, reduced waste production, and shorter manufacturing routes. Key challenge areas, or themes, covered in our partnership include:1. The development and application of Artificial Intelligence (AI) and Machine Learning to the efficient identification of next generation medicines: in Drug Discovery, many hundreds of candidate structures are designed, prepared, and tested to find the molecule with the right profile to take into the clinic. The development of AI informed decision making has the potential to deliver huge savings by minimising the number of compounds that need to be made at this stage. The software developed will incorporate green chemistry principles with the goal that the chemical methods employed are as efficient and sustainable as possible.2. Next generation catalysis and synthesis: Chemists seeking to discover new medicines need new reactions that will allow them to make and investigate structures that are currently difficult, or even impossible, to make. A key objective of this proposal will be to develop new reagents, catalysts, and reactions to facilitate the more efficient preparation of drug-like molecules to accelerate drug discovery. Similarly, we will develop new ways of performing some of the most common chemical transformations in the synthesis of medicines whilst avoiding the use of carcinogenic reagents.3. Sustainable processes that deliver efficiency and transition to scale-up from grammes to kilogrammes. Currently under-utilised approaches, such as electrochemistry, will be explored for their ability to catalyse reactions with cheaper and less environmentally impactful metals, such as replacing palladium with nickel.4. A new Digital Design toolset for equipment will enable Digital Manufacturing of novel pharmaceutical processing equipment. Current development relies on existing traditional vessels and flow reactors that compromise our ability to deliver processes that operate at optimal performance. The research will couple advanced process models, state-of-the-art experimentation, and 3-D printing/additive manufacturing technologies to revolutionise how we develop, scale up, and operate chemical processes to supply new medicines. Integration of the projects and the expertise from the three partner institutions, and the successful prosecution of our research objectives, will make a major contribution to the wider pharmaceutical sector and, indeed, GSK's mission of discovering and developing transformative medicines faster to help people do more, feel better, and live longer.